Cocrystal Pharma 2025 net loss narrows as R&D expenses fall

Reuters03-31

<a href="https://laohu8.com/S/COCP">Cocrystal Pharma</a> 2025 net loss narrows as R&D expenses fall

Overview

US antiviral therapeutics developer's 2025 net loss narrowed yr/yr as R&D expenses declined
Company enrolled first subjects in Phase 1b norovirus challenge study for oral antiviral CDI-988
Cash at year-end fell to $7.7 mln from $9.9 mln a year earlier

Outlook

Company is conducting a Phase 1b norovirus challenge study with CDI-988 at Emory University
Cocrystal plans further development of CDI-988 as a treatment for norovirus and coronaviruses
Company intends to continue development of oral CC-42344 for pandemic and seasonal influenza A

Result Drivers

LOWER R&D SPEND - Co attributed reduced research and development expenses to winddown of Phase 2a influenza study and lower employee-related costs
NOROVIRUS STUDY LAUNCH - Co began Phase 1b norovirus challenge study for oral antiviral candidate CDI-988
LOWER ADMIN COSTS - Co attributed decrease in general and administrative expenses to reduced compensation, insurance and corporate expenses

Company press release: ID:nGNX6NyzbB

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
FY Net Income		-$8.83 mln
FY Basic EPS		-$0.78
FY Operating Expenses		$9.02 mln
FY Operating Income		-$9.02 mln

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2623589516?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-31 20:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2623589516","market":"us","top_or_hot":-1,"title":"Cocrystal Pharma 2025 net loss narrows as R&D expenses fall","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title><a href=\"https://laohu8.com/S/COCP\">Cocrystal Pharma</a> 2025 net loss narrows as R&amp;D expenses fall</title></head><body><p><span>Overview</span></p><ul><li><p>US antiviral therapeutics developer's 2025 net loss narrowed yr/yr as R&amp;D expenses declined</p></li><li><p>Company enrolled first subjects in Phase 1b norovirus challenge study for oral antiviral CDI-988</p></li><li><p>Cash at year-end fell to $7.7 mln from $9.9 mln a year earlier</p></li></ul><p><span>Outlook</span></p><ul><li><p>Company is conducting a Phase 1b norovirus challenge study with CDI-988 at Emory University</p></li><li><p>Cocrystal plans further development of CDI-988 as a treatment for norovirus and coronaviruses</p></li><li><p>Company intends to continue development of oral CC-42344 for pandemic and seasonal influenza A</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>LOWER R&amp;D SPEND - Co attributed reduced research and development expenses to winddown of Phase 2a influenza study and lower employee-related costs</p></li><li><p>NOROVIRUS STUDY LAUNCH - Co began Phase 1b norovirus challenge study for oral antiviral candidate CDI-988</p></li><li><p>LOWER ADMIN COSTS - Co attributed decrease in general and administrative expenses to reduced compensation, insurance and corporate expenses</p></li></ul><p>Company press release: <span>ID:nGNX6NyzbB</span></p><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>FY Net Income</p></td><td></td><td><p>-$8.83 mln</p></td><td></td></tr><tr><td><p>FY Basic EPS</p></td><td></td><td><p>-$0.78</p></td><td></td></tr><tr><td><p>FY Operating Expenses</p></td><td></td><td><p>$9.02 mln</p></td><td></td></tr><tr><td><p>FY Operating Income</p></td><td></td><td><p>-$9.02 mln</p></td><td></td></tr></tbody></table><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cocrystal Pharma 2025 net loss narrows as R&D expenses fall</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCocrystal Pharma 2025 net loss narrows as R&D expenses fall\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-31 20:11</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title><a href=\"https://laohu8.com/S/COCP\">Cocrystal Pharma</a> 2025 net loss narrows as R&amp;D expenses fall</title></head><body><p><span>Overview</span></p><ul><li><p>US antiviral therapeutics developer's 2025 net loss narrowed yr/yr as R&amp;D expenses declined</p></li><li><p>Company enrolled first subjects in Phase 1b norovirus challenge study for oral antiviral CDI-988</p></li><li><p>Cash at year-end fell to $7.7 mln from $9.9 mln a year earlier</p></li></ul><p><span>Outlook</span></p><ul><li><p>Company is conducting a Phase 1b norovirus challenge study with CDI-988 at Emory University</p></li><li><p>Cocrystal plans further development of CDI-988 as a treatment for norovirus and coronaviruses</p></li><li><p>Company intends to continue development of oral CC-42344 for pandemic and seasonal influenza A</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>LOWER R&amp;D SPEND - Co attributed reduced research and development expenses to winddown of Phase 2a influenza study and lower employee-related costs</p></li><li><p>NOROVIRUS STUDY LAUNCH - Co began Phase 1b norovirus challenge study for oral antiviral candidate CDI-988</p></li><li><p>LOWER ADMIN COSTS - Co attributed decrease in general and administrative expenses to reduced compensation, insurance and corporate expenses</p></li></ul><p>Company press release: <span>ID:nGNX6NyzbB</span></p><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>FY Net Income</p></td><td></td><td><p>-$8.83 mln</p></td><td></td></tr><tr><td><p>FY Basic EPS</p></td><td></td><td><p>-$0.78</p></td><td></td></tr><tr><td><p>FY Operating Expenses</p></td><td></td><td><p>$9.02 mln</p></td><td></td></tr><tr><td><p>FY Operating Income</p></td><td></td><td><p>-$9.02 mln</p></td><td></td></tr></tbody></table><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"COCP","symbol_name":"Cocrystal Pharma, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nL1N40J0HT:1","article_id":"2623589516","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2623589516","pubTimestamp":1774959090,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Cocrystal Pharma 2025 net loss narrows as R&D expenses fallOverviewUS antiviral therapeutics developer's 2025 net loss narrowed yr/yr as R&D expenses declinedCompany enrolled first subjects in Phase 1","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"COCP":"Cocrystal Pharma, Inc.","BK4007":"制药"},"translate_title":"随着研发费用下降，Cocrystal Pharma 2025年净亏损收窄","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"COCP":0.9},"content_text":"Cocrystal Pharma 2025 net loss narrows as R&D expenses fallOverviewUS antiviral therapeutics developer's 2025 net loss narrowed yr/yr as R&D expenses declinedCompany enrolled first subjects in Phase 1b norovirus challenge study for oral antiviral CDI-988Cash at year-end fell to $7.7 mln from $9.9 mln a year earlierOutlookCompany is conducting a Phase 1b norovirus challenge study with CDI-988 at Emory UniversityCocrystal plans further development of CDI-988 as a treatment for norovirus and coronavirusesCompany intends to continue development of oral CC-42344 for pandemic and seasonal influenza AResult DriversLOWER R&D SPEND - Co attributed reduced research and development expenses to winddown of Phase 2a influenza study and lower employee-related costsNOROVIRUS STUDY LAUNCH - Co began Phase 1b norovirus challenge study for oral antiviral candidate CDI-988LOWER ADMIN COSTS - Co attributed decrease in general and administrative expenses to reduced compensation, insurance and corporate expensesCompany press release: ID:nGNX6NyzbBKey DetailsMetricBeat/MissActualConsensus EstimateFY Net Income-$8.83 mlnFY Basic EPS-$0.78FY Operating Expenses$9.02 mlnFY Operating Income-$9.02 mlnFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2623589516","isCrawlerRequest":true}